Concomitant targeting of BCL2 with venetoclax and MAPK signaling with cobimetinib in acute myeloid leukemia models

The pathogenesis of acute myeloid leukemia (AML) involves serial acquisition of mutations controlling several cellular processes, requiring combination therapies affecting key downstream survival nodes in order to treat the disease effectively. The BCL2 selective inhibitor venetoclax has potent anti...

Descripción completa

Detalles Bibliográficos
Autores principales: Han, Lina, Zhang, Qi, Dail, Monique, Shi, Ce, Cavazos, Antonio, Ruvolo, Vivian R., Zhao, Yang, Kim, Eugene, Rahmani, Mohamed, Mak, Duncan H., Jin, Sha S., Chen, Jun, Phillips, Darren C., Koller, Paul Bottecelli, Jacamo, Rodrigo, Burks, Jared K., DiNardo, Courtney, Daver, Naval, Jabbour, Elias, Wang, Jing, Kantarjian, Hagop M., Andreeff, Michael, Grant, Steven, Leverson, Joel D., Sampath, Deepak, Konopleva, Marina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ferrata Storti Foundation 2020
Materias:
Aticle
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7049339/
https://www.ncbi.nlm.nih.gov/pubmed/31123034
http://dx.doi.org/10.3324/haematol.2018.205534

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7049339/
https://www.ncbi.nlm.nih.gov/pubmed/31123034
http://dx.doi.org/10.3324/haematol.2018.205534

Ejemplares similares